# Resilience

> Resilience is a VC fund in La Jolla backing Biotechnology and B2B. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: La Jolla, United States
- Total investments: 6
- Last investment: Jun 2023
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/tatleaux-partners-llc/about/
- X (Twitter): https://twitter.com/IncResilience
- Website: https://resilience.com/
- Facebook: https://www.facebook.com/NationalResilience

Resilience is a technology-driven biomanufacturing company committed to expanding access to complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. The company is creating a sustainable network of advanced, end-to-end manufacturing solutions to ensure that today's and tomorrow's treatments can beproduced rapidly, safely, and at scale. By continuously innovating in biopharmaceutical manufacturing and development, Resilience enables its partners to focus on breakthrough discoveries that enhance patient outcomes while safeguarding biopharmaceutical supply chains against future disruptions.

## Contacts

5 contacts available for Resilience. Shizune tracks 17 team members at Resilience. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/resilience-e701?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.2M–$6M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 50% |
| B2B | 1 | 17% |
| IaaS | 1 | 17% |
| AgTech | 1 | 17% |
| Analytics | 1 | 17% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 50% |
| Series A | 1 | 17% |
| Series B | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 50% |
| Mali | 1 | 17% |
| United Kingdom | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bill Reid | CISO and VP, Security and Privacy | 0 | https://shizune.co/investors/profile/bill-reid-2 |
| Eytan Abraham | VP, Head of Cell Therapy Franchise | 0 | https://shizune.co/investors/profile/eytan-abraham |
| Rahul Singhvi | Co-Founder & CEO | 0 | https://shizune.co/investors/profile/rahul-singhvi |
| Ross Leimberg | Senior Director of Business Development | 0 | https://shizune.co/investors/profile/ross-leimberg |
| Sandy Mahatme | President, COO and CFO | 0 | https://shizune.co/investors/profile/sandesh-mahatme |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PartnerSlate | PartnerSlate is an online platform that helps food and beverage brands make the right strategic partnerships to get their next product to market. Brands can discover, connect, and build relationships with contract manufacturers and other food industry partners across North America. | $4M | Seed | Jun 09, 2023 |  |
| Cellevolve | Cellevolve Bio is a development and commercialization company focused on cell therapies. | $6M | Seed | Nov 18, 2021 |  |
| Cellevolve | Cellevolve Bio is a development and commercialization company focused on cell therapies. | $6M | Seed | Nov 18, 2021 |  |
| bit.bio | Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development. The company uses a precision cell programming system to convert stem cells into defined human cell types and supplies a portfolio of reprogrammed cells, custom cell development services, and research-readyhuman cell models for scientific and pharmaceutical use. Bit.bio also supports integration of its products into partner research ecosystems and offers platform capabilities that help identify transcription factors for specific cell states. Its focus includes enabling scalable access to human cell models for experiments, screening workflows, and therapeutic investigation. | $103M | Series B | Nov 05, 2021 |  |
| Stratus Therapeutics | Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases. | $72M | Series A | Sep 23, 2021 |  |
| OKO | OKO uses satellite information to define risk and create insurance products for farmers in emerging markets. They use mobile technologies to distribute insurance, collect premiums, help farmers and pay claims. | $1.2M | Seed | Apr 21, 2021 |  |

6 of 6 investments shown.

## Co-investors
- [Hibiscus BioVentures](https://shizune.co/investors/profile/hibiscus-bioventures) — VC Fund, 2 deals together
- [Jumpstart Health Investors](https://shizune.co/investors/profile/jumpstart-health-investors) — VC Fund, 2 deals together
- [THE CATALYTIC IMPACT FOUNDATION (CIF)](https://shizune.co/investors/profile/the-catalytic-impact-foundation-cif) — VC Fund, 2 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together
- [ArchVentures SA](https://shizune.co/investors/profile/archventures-sa) — VC Fund, 1 deal together
- [Charles River Laboratories International](https://shizune.co/investors/profile/charles-river-laboratories-international) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [E3 Capital](https://shizune.co/investors/profile/energy-access-ventures) — VC Fund
- [Mercy Corps Ventures](https://shizune.co/investors/profile/mercy-corps-ventures) — VC Fund
- [AfricInvest](https://shizune.co/investors/profile/afric-invest) — VC Fund

## Featured in investor lists
- [All Investors in Mali](https://shizune.co/investors/investors-mali)
- [All VC Funds in Mali](https://shizune.co/investors/vc-funds-mali)
- [InsurTech Investors in Africa](https://shizune.co/investors/insurtech-investors-africa)
- [FinTech Investors in Mali](https://shizune.co/investors/fintech-investors-mali)
- [SaaS Investors in Mali](https://shizune.co/investors/saas-investors-mali)
- [Agriculture (agtech) Investors in Mali](https://shizune.co/investors/agriculture-agtech-investors-mali)

## FAQ

### What does Resilience invest in?

Resilience invests primarily in Biotechnology, B2B and IaaS startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Resilience's check size?

Resilience typically joins rounds of $1.2M–$6M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Resilience participates in.

### How do I contact Resilience?

Public channels for Resilience include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Resilience?

The team at Resilience includes Bill Reid (CISO and VP, Security and Privacy), Eytan Abraham (VP, Head of Cell Therapy Franchise) and Rahul Singhvi (Co-Founder & CEO), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co